PTC Therapeutics (PTCT) Buy Rating Maintained at Deutsche Bank
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
PTC Therapeutics (PTCT) Pares Move Higher Following M&A Speculation (BMRN)
February 23, 2015 12:28 PM ESTPTC Therapeutics (NASDAQ: PTCT) is paring some gains related to M&A speculation. One noted biotech watcher thinks a move for BioMarin (Nasdaq: BMRN) to acquire PTCT is unlikely.
$BMRN is interested in buying $PTCT? Thats hard to believe.
— Adam Feuerstein (@adamfeuerstein) February 23, 2015... More
UPDATE: PTC Therapeutics (PTCT) pops; said to be exploring possible sale - Reuters
February 23, 2015 12:03 PM EST(Updated - February 23, 2015 12:43 PM EST)
PTC Therapeutics (NASDAQ: PTCT) pops on chatter the company is exploring a sale, according to Reuters headlines.
According to the report, the company has received takeover interest from several pharmaceutical companies including Shire plc (NASDAQ:... More
